

Resource Summary Report

Generated by [NIF](#) on Aug 29, 2026

EnVision Manager

RRID:SCR_016681

Type: Tool

Proper Citation

EnVision Manager (RRID:SCR_016681)

Resource Information

URL: <http://envision.bioe.orst.edu/Downloads.aspx>

Proper Citation: EnVision Manager (RRID:SCR_016681)

Description: Envision Manager is a multi-user control system management and monitoring software. Software used to manage EnVision Multimode microplate readers (Part Number 2105-0010 by Parking Elmer).

Resource Type: software application, software resource

Keywords: control, system, management, monitoring, software

Availability: Free, Available for download, Freely available

Resource Name: EnVision Manager

Resource ID: SCR_016681

Alternate URLs: <http://www.perkinelmer.com/product/envision-hts-plate-reader-2105-0010>

Record Creation Time: 20220129T080331+0000

Record Last Update: 20260821T042944+0000

Ratings and Alerts

No rating or validation information has been found for EnVision Manager.

No alerts have been found for EnVision Manager.

Data and Source Information

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Williams JS, et al. (2026) Patient-derived pediatric brain tumor orthotopic xenografts and tumor organoids faithfully recapitulate primary tumors. Science advances, 12(16), eaea4966.

Saotome K, et al. (2025) Structural insights into CXCR4 modulation and oligomerization. Nature structural & molecular biology, 32(2), 315.

Simoneau A, et al. (2025) Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency. Molecular cancer therapeutics, 24(5), 678.

Bharath N, et al. (2025) A novel high-throughput screening platform to identify inhibitors of DNAJB1-PRKACA-driven transcriptional activity in fibrolamellar carcinoma. SLAS discovery : advancing life sciences R & D, 32, 100221.

Pourmal S, et al. (2025) Autoinhibition of dimeric NINJ1 prevents plasma membrane rupture. Nature, 637(8045), 446.

Fraguas Bringas C, et al. (2025) Mechanism and cellular actions of the potent AMPK inhibitor BAY-3827. Science advances, 11(34), eadx2434.

Mittal K, et al. (2024) Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin. Communications biology, 7(1), 426.

Bashore C, et al. (2023) Targeted degradation via direct 26S proteasome recruitment. Nature chemical biology, 19(1), 55.

Kayagaki N, et al. (2023) Inhibiting membrane rupture with NINJ1 antibodies limits tissue injury. Nature.

Simoneau A, et al. (2023) Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer. Molecular cancer therapeutics, 22(2), 215.

Sharifnia T, et al. (2023) Mapping the landscape of genetic dependencies in chordoma. Nature communications, 14(1), 1933.

Meroni A, et al. (2022) NEDDylated Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors. Science advances, 8(49), eabq0648.

Pedersen AKN, et al. (2022) Sitagliptin reduces FAP-activity and increases intact FGF21 levels in patients with newly detected glucose abnormalities. Molecular and cellular endocrinology, 556, 111738.

Bagley JD, et al. (2021) Significant Capacitance Enhancement via In Situ Exfoliation of Quasi-One-Dimensional Graphene Nanostripes in Supercapacitor Electrodes. ACS omega, 6(8), 5679.

Antonyshyn JA, et al. (2021) Mitigating the non-specific uptake of immunomagnetic microparticles enables the extraction of endothelium from human fat. Communications biology, 4(1), 1205.

Tirman S, et al. (2021) Temporally distinct post-replicative repair mechanisms fill PRIMPOL-dependent ssDNA gaps in human cells. Molecular cell, 81(19), 4026.

Bagley JD, et al. (2020) Selective formation of pyridinic-type nitrogen-doped graphene and its application in lithium-ion battery anodes. RSC advances, 10(65), 39562.

Ostertag MS, et al. (2019) Structural Insights into BET Client Recognition of Endometrial and Prostate Cancer-Associated SPOP Mutants. Journal of molecular biology, 431(11), 2213.

Yan X, et al. (2019) Replication Study: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. eLife, 8.

Fallacara AL, et al. (2019) A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor. Cancers, 11(6).